# **Supplemental Data Rif1 and Rif2 inhibit localization of Tel1 to DNA ends Y. Hirano, K. Fukunaga and K. Sugimoto**

## **I. Supplemental Experimental Procedures**

## **Strains**

The TG<sub>162</sub>-HO cassette was constructed from the TG $_{81}$ -HO cassette (Hirano and Sugimoto, 2007). An *Mfel* site was introduced into the TG<sub>81</sub> sequence by PCR amplification. The resulting PCR fragment was digested with *Mfe*I and *Not*I, and cloned into the *EcoRI/Not*I sites of pTG-HO (Hirano and Sugimoto, 2007), creating pTG<sub>162</sub>-HO. The TetO<sub>2</sub>, TetO<sub>4</sub>, or TetO<sub>8</sub> construct was obtained as follows. First, two oligonucleotides were annealed to generate a TetO $_2$  array containing two copies of the 19 bp *tetO* promoter sequence (Dingermann et al., 1992). TetO<sub>2</sub> was first cloned into the *Eco*RI/*Xho*I sites of pSD155 (Diede and Gottschling, 1999, 2001), generating ptetO<sub>2</sub>. To duplicate the TetO<sub>2</sub> sequence, the *Mfel-Notl* fragment of ptetO<sub>2</sub> was cloned into *EcoRI/Not*I-treated ptetO<sub>2</sub>, generating ptetO<sub>4</sub>. Likewise, ptetO<sub>8</sub>was obtained using ptetO4. These plasmids were treated with *Eco*RI and *Sal*I. The resulting *Eco*RI-*Sal*I fragments containing the TetO<sub>2</sub>, TetO<sub>4</sub> or TetO<sub>8</sub> sequence were cloned into *Mfel/Sal*Itreated pHO plasmid (Hirano and Sugimoto, 2007), generating ptetO<sub>2</sub>-HO, ptetO<sub>4</sub>-HO or ptetO<sub>8</sub>-HO, respectively. Oligonucleotides containing four copies of *lacO* sequence (Lewis, 2005), were used to generate the plac $O_4$  plasmid containing the Lac $O_4$ sequence. To duplicate the LacO<sub>4</sub> sequence, the *Mfel-Notl* fragment of placO<sub>4</sub> was cloned into *EcoRI/Not*I-treated placO<sub>4</sub>, generating placO<sub>8</sub>. As the ptetO8 was constructed above, placO<sub>16</sub> was obtained using placO<sub>8</sub>. The *Mfel-Notl* fragment containing the TG<sub>81</sub> sequence was cloned into *EcoRI/Not*I-treated pLacO<sub>16</sub>-HO, generating pLacO<sub>16</sub>-TG<sub>81</sub>-HO. All the above plasmids were digested with *Notl* and *Sall* to integrate the cassettes into the *MAT*a-inc strain (Nakada et al., 2003a). Cells containing the LacO<sub>16</sub>-TG<sub>81</sub>-HO cassette were obtained by using the  $pLacO_{16}$ -TG<sub>81</sub>-HO plasmid. Cells containing the  $TG_{162}$ -HO, tetO<sub>2</sub>-HO, tetO<sub>4</sub>-HO, tetO<sub>8</sub>-HO or LacO<sub>16</sub>- $TG_{81}$ -HO cassette were generated by the plasmid pTG<sub>162</sub>-HO, ptetO<sub>2</sub>-HO, ptetO<sub>4</sub>-HO, ptetO8-HO or pLacO16-TG81-HO, respectively. Epitope tagging of *RAP1*, *RIF1* and *RIF2*

was performed by a PCR-based strategy (Hirano and Sugimoto, 2006; Knop et al., 1999). Cells carrying a *rif1* $\Delta$ *, rif2* $\Delta$ *, sir2* $\Delta$  or *tel1* $\Delta$  mutation were obtained by transformation with PCR fragments marked with *LEU2* (Wakayama et al., 2001), *URA3* (Reid et al., 2002) or *HphMX4* (Goldstein and McCusker, 1999)*.* Precise integration of each construct was confirmed by PCR. Other mutations were described previously (Hirano and Sugimoto, 2007; Nakada et al., 2003a; Nakada et al., 2003b; Wakayama et al., 2001).

#### **Plasmids**

To obtain the tetR-fusion gene constructs, the *tetR* coding sequence was amplified by PCR from pCM224 (Belli et al., 1998), adding the SV40 nuclear localization sequence (CTPPKKKRKVA) at its C-terminus. The PCR fragment was digested with *Sal*I and *Sac*I, and cloned into the *Sal*I/*Sac*I sites of YCplac33 (Gietz and Sugino, 1988) carrying a truncated version of the *ADH1* promoter, generating ptetR. The *Sac*II-*Sac*I fragments containing the *RIF1*, *RIF2* or *RAP1* coding sequence were cloned into *Sac*II-*Sac*I treated ptetR, resulting in ptetR-RIF1, ptetR-RIF2 or ptetR-RAP1, respectively. The *Sac*II-*Sac*I fragments containing the HA-epitope fused *RIF1* or *RIF2* coding sequence were cloned into *Sac*II/*Sac*I-treated ptetR, resulting in ptetR-RIF1-HA or ptetR-RIF2-HA, respectively. The *lacI* coding sequence with the SV40 nuclear localization signal was amplified from pAFS78 (Straight et al., 1996) fusing an FLAG epitope at the C-terminus. The PCR fragment was digested with *Sal*I and *SacI*, and cloned into the *Sal*I/*Sac*I sites of YCplac33 carrying a truncated version of the *ADH1* promoter, generating pLacI-FLAG. Fragments containing the *GAL10* promoter or encoding an N-terminal Tel1 region were amplified by PCR, adding one FLAG epitope to each fragment, and digested with *Not*I and *Ngo*MIV or *Ngo*MIV and *Rsr*II, respectively. These fragments were cloned into *Not*I/*Rsr*II-treated pDM196 (Morrow et al., 1995), generating pGAL-FLAG-TEL1. To create pGST-XRS2C, the C-terminus of Xrs2 (amino acids 474-854) was amplified by PCR and cloned into pGEX-6P-1 (GE Healthcare). To express His-Rif2-FLAG proteins, the coding sequence of *RIF2* was amplified by PCR, adding the sequence encoding two FLAG epitopes at the C-terminus. The PCR fragment was digested with *Eco*RI and *Sac*I, and cloned into pET28a (Novagen), generating pET-RIF2-FLAG. Fragments containing an N-terminal (amino acids 1-170), a central (amino

acids 91-250), or C-terminal (amino acids 171-395) region of Rif2 were obtained after PCR amplification and cloned into pET28a, creating pET-RIF2(1-170), pET-RIF2(91- 250) or pET-RIF2(171-395). pET28a contains the sequences encoding His- and T7 tags. The same *RIF2* PCR fragments and a fragment encoding three myc epitopes were cloned into ptetR, resulting in ptetR-RIF2(1-170), ptetR-RIF2(91-250) or ptetR-RIF2(171-395). YCpA-GAL-HO was previously described (Nakada et al., 2003a). The pYtel plasmid containing a telomeric TG repeat was obtained from A. Matsuura.

## **PCR primer for ChIP assay**

The sequences of primers for the HO set were 5'-

GTTGTTTCTGAAACATGGCAAAGG-3' and 5'-CAACCAAACCGTTATTCATTCGTG-3', and those for the *SMC2* locus were 5'- AAAGACTGAGCTGAATGAAGTCTC -3' and 5'- CGTCTGAGAATCTTGAACAACAAC -3'. The primers for the telomere VL-R and XV-L were synthesized as described previously (Fisher et al., 2004; Hector et al., 2007).

## **Protein purification**

FLAG-Tel1 proteins were purified from budding yeast cells. Cells carrying pGAL-FLAG-TEL1 were cultured in medium containing 2% galactose for 5 h. Cells were suspended in the lysis buffer (20 mM Tris-HCl at pH 8.0, 0.1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 40 mM  $\beta$ -glycerophosphate, 15 mM  $\rho$ -NO<sub>2</sub>phenylphosphate, 1  $\mu$ g/ml of leupeptin, 1  $\mu$ g/ml of pepstatin, 0.5% aporotinin, 1 mM PMSF) and physically disrupted with glass beads. After centrifugation, supernatants were incubated with anti-FLAG M2 affinity gel (Sigma) at 4°C for 2 h. The beads were washed three times with the lysis buffer and bound proteins were eluted with the elution buffer (20 mM Tris-HCl at pH 8.0, 0.01% Triton X-100, 100 mM NaCl) containing 150 g/ml of 3xFLAG peptides (Sigma). GST or GST-Xrs2C proteins were prepared from *E. coli* carrying pGEX-6P-1 or pGST-XRS2C, respectively. After induction with IPTG for 3 hr, GST proteins were purified using glutathione Sepharose according to the manufacturer's instructions (GE healthcare). His-Rif2-FLAG or His-Rif2 fragments were purified from *E. coli*. Cells transformed with pET-RIF2-FLAG, pET-RIF2 (1-170), pET-RIF2 (91-250) or pET-RIF2 (171-395) were cultured at 19°C for 14 hr in the presence of IPTG. Proteins were purified on a Ni-column (Novagen) as suggested by the

manufacturer. FLAG-tagged proteins were further purified on anti-FLAG M2 affinity gel as above.

## **II. Supplemental Figures**



#### **TetR-Rif1 or TetR-Rif2.**

HO cells expressing Tel1-HA were transformed with ptetR-RIF1, ptetR-RIF2 or the control vector, together with the GAL-HO plasmid, and analyzed by ChIP assay as in Fig. 1C. Strains used contain a *rap1-C* mutation.

*rap1-C* mutation.



### **Fig. 5S. Association of Tel1 with DSBs near the**  TetO<sub>8</sub> array in cells expressing TetR by itself.  $TetO_8$ -HO cells expressing Tel1-HA were transformed with ptetR or the control vector, together with the GAL-HO plasmid, and analyzed by ChIP assay as in Fig. 1C. Strains used contain a



#### **Fig. 6S. Association of Mec1 with DSBs near the TetO<sub>8</sub> array in cells expressing TetR-Rif1 or TetR-Rif2.**

 $TetO_8$ -HO cells expressing Mec1-HA were transformed with ptetR-RIF1, ptetR-RIF2 or the control vector, together with the GAL-HO plasmid, and analyzed by ChIP assay as in Fig. 1C. Strains used contain a *rap1-C* mutation.



Fig. 7S. Mre11 association with TetO<sub>4</sub> or TetO<sub>2</sub> ends in cells expressing TetR-Rif1 **or TetR-Rif2 proteins.**

TetO<sub>4</sub>-HO (A) or TetO<sub>2</sub>-HO (B) expressing Mre11-myc were transformed with ptetR-RIF1, tetR-RIF2 or the control vector, together with the GAL-HO plasmid, and analyzed by ChIP assay as in Fig. 1C. Strains used contain a *rap1-C* mutation.





TetO4-HO cells expressing Tel1-HA were transformed with ptetR-RIF1 or the control vector, together with the GAL-HO plasmid, and analyzed by ChIP assay as in Fig. 1C. Strains used were wild-type, *rif1* a single, *rif2* a single or *rif1* a *rif2* double mutant cells.



#### **Fig. 9S. Effect of** *tel1-KN* **or** *tel1* **mutation on the length of endogenous telomeres.**

Genomic DNA was prepared from cells and digested by XhoI, and analyzed by Southern blot using the EcoRV-XhoI fragment from the pYtel plasmid as a probe. Two independent colonies of wild-type, *tel1- KN* and  $te/1\Delta$  mutants used in Fig. 4E were analyzed.



#### **Fig. 10S. Effect of** *tel1* **on association of Mre11 with TG<sub>162</sub> ends.**

TG<sub>162</sub>-HO cells expressing Mre11-myc were analyzed by ChIP assay as in Fig. 1C.



**Fig. 11S. Effect of TetR-Rap1 expression on Tel1 association in**   $\mathbf{r}$ *if1* $\Delta$ *rif2* $\Delta$  **cells.** TetO<sub>8</sub>-HO or TetO<sub>8</sub>-HO rif1 $\triangle$  rif2 $\triangle$  cells expressing Tel1-HA were transformed with ptetR-RAP1 or the control vector, together with the GAL-HO plasmid, and analyzed as in Fig. 1C to monitor Tel1 association. The strains used here contain a *sir2∆* mutation to rescue defective HO cleavage.



**Fig. 12S. Purification of His-Rif2- FLAG protein from** *E. coli***.** 

Purified His-Rif2-FLAG proteins were separated on 12% SDS-PAGE and stained win Coomassie Brilliant Blue. The left lane contains protein molecular-weight standard (M). BSA was loaded to estimate protein concentration.

## **III. References**

Belli, G., Gari, E., Aldea, M., and Herrero, E. (1998). Functional analysis of yeast essential genes using a promoter-substitution cassette and the tetracycline-regulatable dual expression system. Yeast *14*, 1127-1138.

Diede, S.J., and Gottschling, D.E. (1999). Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta. Cell *99*, 723-733. Diede, S.J., and Gottschling, D.E. (2001). Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere. Curr Biol *11*, 1336-1340.

Dingermann, T., Frank-Stoll, U., Werner, H., Wissmann, A., Hillen, W., Jacquet, M., and Marschalek, R. (1992). RNA polymerase III catalysed transcription can be regulated in Saccharomyces cerevisiae by the bacterial tetracycline repressor-operator system. EMBO J *11*, 1487-1492.

Fisher, T.S., Taggart, A.K., and Zakian, V.A. (2004). Cell cycle-dependent regulation of yeast telomerase by Ku. Nat Struct Mol Biol *11*, 1198-1205.

Gietz, R.D., and Sugino, A. (1988). New yeast-*Escherichia coli* shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene *74*, 527-534.

Goldstein, A.L., and McCusker, J.H. (1999). Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae. Yeast *15*, 1541-1553. Hector, R.E., Shtofman, R.L., Ray, A., Chen, B.R., Nyun, T., Berkner, K.L., and Runge, K.W. (2007). Tel1p preferentially associates with short telomeres to stimulate their elongation. Mol Cell *27*, 851-858.

Hirano, Y., and Sugimoto, K. (2006). ATR homolog Mec1 controls association of DNA polymerase zeta-Rev1 complex with regions near a double-strand break. Curr Biol *16*, 586-590.

Hirano, Y., and Sugimoto, K. (2007). Cdc13 telomere capping decreases Mec1 association but does not affect Tel1 association with DNA ends. Mol Biol Cell *18*, 2026- 2036.

Knop, M., Siegers, K., Pereira, G., Zachariae, W., B, B.W., Nasmyth, K., and Schiebel, E.

(1999). Epitope tagging of yeast genes using a PCR-based strategy: more tags and improved practical routines. Yeast *15*, 963-972.

Lewis, M. (2005). The lac repressor. C R Biol *328*, 521-548.

Morrow, D.M., Tagle, D.A., Shiloh, Y., Collins, F.S., and Hieter, P. (1995). *TEL1*, an *S. cerevisiae* homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene *MEC1*. Cell *82*, 831-840.

Nakada, D., Matsumoto, K., and Sugimoto, K. (2003a). ATM-related Tel1 associates with double-strand breaks through an Xrs2-dependent mechanism. Genes & Dev *17*, 1957-1962.

Nakada, D., Shimomura, T., Matsumoto, K., and Sugimoto, K. (2003b). The ATM-related Tel1 protein of *Saccharomyces cerevisiae* controls a checkpoint response following phleomycin treatment. Nucleic Acids Res *31*, 1715-1724.

Reid, R.J., Lisby, M., and Rothstein, R. (2002). Cloning-free genome alterations in Saccharomyces cerevisiae using adaptamer-mediated PCR. Methods Enzymol *350*, 258-277.

Straight, A.F., Belmont, A.S., Robinett, C.C., and Murray, A.W. (1996). GFP tagging of budding yeast chromosomes reveals that protein-protein interactions can mediate sister chromatid cohesion. Curr Biol *6*, 1599-1608.

Wakayama, T., Kondo, T., Ando, S., Matsumoto, K., and Sugimoto, K. (2001). Pie1, a protein interacting with Mec1, controls cell growth and checkpoint responses in *Saccharomyces cerevisiae.* Mol Cell Biol *21*, 755-764.